MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 03-03-2026
Agilent Technologies Total Non Current Liabilities 2011-2026 | A
Annual Total Non Current Liabilities Agilent Technologies
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 3.29 B | 2.62 B | 2.8 B | 2.33 B | 2.61 B | 2.33 B | 3.83 B | 3.8 B | 3.46 B | 2.9 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.83 B | 2.33 B | 3 B |
Total Non Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
527 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
23.7 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
134 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Chembio Diagnostics
CEMI
|
24.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
574 K | $ 1.63 | -1.21 % | $ 2.17 M | USA |
 |
Aspira Women's Health
AWH
|
3.49 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
11.3 M | - | -13.05 % | $ 7.29 M | USA |
 |
Castle Biosciences
CSTL
|
2.76 M | $ 24.92 | -0.24 % | $ 692 M | USA |
 |
Check-Cap Ltd.
CHEK
|
16 K | - | - | $ 9.42 M |  Israel |
 |
Enzo Biochem
ENZ
|
4.6 M | - | -8.98 % | $ 14.8 K | USA |
 |
CareDx, Inc
CDNA
|
17.9 M | $ 21.77 | -0.39 % | $ 1.16 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
7.74 M | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
865 K | - | -11.32 % | $ 2.94 M | USA |
 |
Illumina
ILMN
|
2.04 B | $ 126.99 | -1.19 % | $ 20.2 B | USA |
 |
Exact Sciences Corporation
EXAS
|
981 M | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
2.26 M | $ 15.36 | -1.54 % | $ 464 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
4.1 M | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
2.53 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
131 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
559 K | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
48.5 M | - | 0.12 % | $ 80.1 M | China |
 |
Lantheus Holdings
LNTH
|
225 M | $ 83.55 | -0.67 % | $ 5.64 B | USA |
 |
Charles River Laboratories International
CRL
|
2.35 B | $ 167.01 | -2.46 % | $ 8.28 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.43 B | - | - | $ 10.7 B | USA |
 |
Guardant Health
GH
|
91.4 M | $ 83.91 | -5.19 % | $ 10.5 B | USA |
 |
Heska Corporation
HSKA
|
57.9 M | - | - | $ 1.31 B | USA |
 |
National Research Corporation
NRC
|
39.6 M | $ 17.0 | -0.64 % | $ 381 M | USA |
 |
Interpace Biosciences
IDXG
|
10 M | $ 1.93 | -2.08 % | $ 8.54 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
8.08 B | $ 26.96 | -2.12 % | $ 20 B |  Niderland |
 |
Precipio
PRPO
|
1.9 M | $ 30.53 | -0.57 % | $ 49 M | USA |
 |
Personalis
PSNL
|
639 K | $ 5.71 | -4.19 % | $ 338 M | USA |
 |
Medpace Holdings
MEDP
|
73.8 M | $ 421.99 | 0.15 % | $ 12.2 B | USA |
 |
Senseonics Holdings
SENS
|
163 M | $ 7.34 | 0.94 % | $ 306 M | USA |
 |
QIAGEN N.V.
QGEN
|
1.99 B | - | - | $ 10.6 B | Niderland |
 |
Motus GI Holdings
MOTS
|
2.16 M | - | -34.28 % | $ 263 K | Israel |
 |
Biomerica
BMRA
|
1.57 M | $ 2.18 | - | $ 5.01 M | USA |
 |
ICON Public Limited Company
ICLR
|
461 M | $ 101.59 | -1.57 % | $ 8.38 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
7.82 B | $ 261.82 | -0.61 % | $ 21.8 B | USA |
 |
Thermo Fisher Scientific
TMO
|
22.5 B | $ 467.85 | -0.04 % | $ 176 B | USA |
 |
Neogen Corporation
NEOG
|
19.6 M | $ 9.32 | -1.38 % | $ 2.02 B | USA |
 |
Celcuity
CELC
|
69.2 K | $ 122.43 | -2.59 % | $ 5.72 B | USA |
 |
Trinity Biotech plc
TRIB
|
106 M | $ 0.63 | -1.88 % | $ 61.9 M | Irlanda |
 |
NeoGenomics
NEO
|
435 M | $ 8.71 | 1.1 % | $ 1.12 B | USA |
 |
Twist Bioscience Corporation
TWST
|
4.56 M | $ 58.84 | -3.54 % | $ 3.52 B | USA |
 |
Myriad Genetics
MYGN
|
107 M | $ 4.87 | 0.72 % | $ 451 M | USA |
 |
Natera
NTRA
|
124 M | $ 199.87 | -2.21 % | $ 19.7 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
5.17 B | $ 196.14 | -0.2 % | $ 21.8 B | USA |
 |
Invitae Corporation
NVTA
|
320 M | - | - | $ 21.2 M | USA |
 |
OpGen
OPGN
|
21.2 M | - | -16.95 % | $ 1.54 M | USA |